NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Research
Written by / Agency / Source: Becton, Dickinson and Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis - BD Life Sciences announced it has completed the acquisition of Cellular Research, Inc. - Cellular-Research.com / BD.com
BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis

 

NewswireToday - /newswire/ - Franklin Lakes, NJ, United States, 2015/08/25 - BD Life Sciences announced it has completed the acquisition of Cellular Research, Inc. - Cellular-Research.com / BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company), today announced it has completed the acquisition of Cellular Research, Inc.

BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years of experience in developing cell sorting technologies, known collectively as flow cytometry. This acquisition sets the stage for the next generation of commercial tools in the field of single cell genomic analysis, widely acknowledged by leading academic and industry researchers as the next frontier of biological discovery and clinical advancement. Cellular Research has developed advanced tools for massively parallel single cell genetic analysis based on their proprietary Molecular Indexing technology to enable gene expression profiles from single cells.

Combined, the BD and Cellular Research technologies provide researchers an integrated sample prep workflow to quantify and study gene expression in large numbers of individual cells, enabling higher resolution biology. The comprehensive workflow is intended to enable researchers to make new discoveries in single cell analysis, promoting the understanding of the genomic diversity of single cells and helping to identify new approaches for targeted clinical diagnostics and therapies in important fields such as immunology, immune-oncology and personalized medicine.

“The acquisition of Cellular Research, combined with our existing cell sorting technology, will provide our customers with a more complete and simplified workflow solution for single cell analysis,” said Linda Tharby, executive vice president and president of BD Life Sciences. “The addition of Cellular Research builds on our GenCell acquisition and underscores BD’s commitment to a genomics strategy focused on next generation sequencing (NGS) sample preparation.”

Since September 2014, BD and Cellular Research have had a collaboration to develop single cell analysis workflows for Cellular Research’s Precise product line and BD’s FACS™ instruments and software. The collaboration resulted in a study presented at Advances in Genome Biology and Technology (AGBT) Meeting that demonstrated the combined workflow enhances the detection and quantification of gene expression in single and/or multiple cell samples.

“Integrating BD’s single cell sorting capabilities and world-leading expertise with our next generation single cell genomic technologies will provide researchers with a scalable, cost-effective approach to high resolution gene expression studies,” said Stephen Fodor, Ph.D., chief executive officer and co-founder of Cellular Research. “We are excited about the possibilities we can offer researchers by combining our expertise, and believe it has the potential to meet several unmet needs in single cell genomics research.”

Additional terms of the agreement were not disclosed.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit bd.com.

About Cellular Research, Inc.
Cellular Research, Inc. is a biotechnology research and development company founded by innovators from Silicon Valley and Stanford University. Our mission is to develop and commercialize a new generation of highly sensitive life science technologies and products. In addition to introducing a portfolio of research products, the Company has an active partnership program with pharmaceutical and diagnostics companies advancing clinical applications. For more information, please visit cellular-research.com/ and follow us on Twitter [.]Cell_Research.



This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding the acquisition of Cellular Research, Inc. These forward-looking statements may be identified by the use of the words "believe","expect" or other words of similar meaning in conjunction with statements regarding the potential impact of the acquisition. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: the ability to successfully integrate Cellular Research’s operations and programs with BD's and the time and resources required to do so; difficulties inherent in product development and delays in product introductions; the extent of market acceptance of the Cellular Research products and other competitive factors; pricing and market pressures; as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contacts:
BD Public Relations: Troy Kirkpatrick
P: 858-617-2361 - E: troy.kirkpatrick[.]carefusion.com.

Cellular Research: Martin Pieprzyk
P: 650-752-6144 - E: mpieprzyk[.]cellular-research.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Monique N. Dolecki - BD.com 
201-847-5378 monique_dolecki[.].com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Becton, Dickinson and Company / Company Profile


Read Research Most Recent Related Newswires:

BASF Formaldpure™ Catalyst Receives 2022 Edison Patent Award
BASF Presents New Research Findings and Novelties in Applied Methods Technologies At IFSCC Congress
Benchtop FT-NMR Applied to SARS-CoV-2 and ‘Long COVID’ Research Lowers the Barrier to Clinical Translation
The Outbreak of COVID-19 Unlocked the Demand for Antimicrobial Technologies Says Frost & Sullivan
World Congress DSA 2023 - The Frontiers in Intelligent Data and Signal Analysis, New York, USA, July
Optina Diagnostics Earns Frost & Sullivan’s 2022 North American Technology Innovation Leadership Award for Leveraging Innovative Eye Imagery
ZAGENO Applauded by Frost & Sullivan for Simplifying the Supply Chain for Life Science Research with its e-Commerce Platform
Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment
Otto Schott Research Award Recognizes Achievements in Glass Science
Swave, A New Imec and VUB, Spin-off, Raises €7M to Deliver Truly Realistic AR/VR Experiences to Applications Like The Metaverse
Frost & Sullivan Awards EBSCO Information Services for Delivering Innovative Solutions to Access Medical Research Information for Healthcare Providers
Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® A Revolutionary, Methane-Reducing Feed Additive for Cattle
Canopy Biosciences Launches the First of a Series of Targeted Assay Kits for ChipCytometry
Safran Teams Up with the University of Limoges, CNRS and the National Research Agency to Inaugurate the Joint X-SELANS Lab
DSM’s Global Head Office to Move to Maastricht, The Netherlands

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)